Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 5/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21165912 | 0.85 | IDH1 (0.34) | IDH1PDE2A | |
| SCHEMBL19687351 | 0.85 | IDH1 (0.40) | IDH1PDE2ANPC1MAPTRAB9A | |
| SCHEMBL21144169 | 0.85 | IDH1 (0.40) | IDH1PDE2ANPC1MAPTRAB9A | |
| SCHEMBL31127144 | 0.85 | IDH1 (0.40) | IDH1PDE2ANPC1MAPTRAB9A | |
| SCHEMBL19686405 | 0.84 | IDH1 (0.39) | IDH1PDE2ANPC1MAPTRAB9A | |
| SCHEMBL19687079 | 0.84 | IDH1 (0.39) | IDH1PDE2ANPC1MAPTRAB9A | |
| SCHEMBL31127120 | 0.84 | IDH1 (0.39) | IDH1PDE2ANPC1MAPTRAB9A | |
| SCHEMBL31127359 | 0.83 | IDH1 (0.35) | IDH1CNR1 | |
| SCHEMBL19687101 | 0.83 | IDH1 (0.35) | IDH1CNR1 | |
| SCHEMBL21165983 | 0.83 | IDH1 (0.39) | IDH1PDE2ANPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| WO-2017139697-A9 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885PDE2A 758/4885CNR1 770/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885PDE2A 758/4885CNR1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.